Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Genzyme's Lemtrada™ Approved in Brazil for Treatment of Multiple Sclerosis
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.
New insights into signaling during myelination in zebrafish.
Alemtuzumab for the Treatment of Multiple Sclerosis
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration.
Daclizumab discontinue letter for the US market
No Differences Observed among Multiple Clinical S1P1 Receptor Agonists (Functional Antagonists) in S1P1 Receptor Down-regulation and Degradation.
Stopping Disease Modifying Therapy in Progressive Multiple Sclerosis - A Prospective Study
Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Minocycline added to subcutaneous interferon β-1a in multiple sclerosis: randomized RECYCLINE study.
Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Teriflunomide (Aubagio) approved for use by the NHS in Scotland and Northern Ireland
Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.
Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT™).
The immunopathology of multiple sclerosis: an overview.
One calcitriol dose transiently increases Helios(+)FoxP3(+) T cells and ameliorates autoimmune demyelinating disease.
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies.
JC Virus in CD34+ and CD19+ Cells in Patients With Multiple Sclerosis Treated With Natalizumab.
Alemtuzumab
Gender identity disorders and multiple sclerosis risk: A national record-linkage study.
Plasma osteopontin levels are associated with disease activity in the patients with multiple sclerosis and neuromyelitis optica.
Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone.

Pages